QNCX — Quince Therapeutics Income Statement
0.000.00%
- $32.41m
- -$21.89m
- 25
- 49
- 26
- 25
Annual income statement for Quince Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 39.2 | 78.9 | 90.3 | 52 | 34.7 |
Operating Profit | -39.2 | -78.9 | -90.3 | -52 | -34.7 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -37 | -76.8 | -89.9 | -51.9 | -31.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | -37 | -76.8 | -89.9 | -51.7 | -31.4 |
Net Income Before Extraordinary Items | |||||
Net Income | -37 | -76.8 | -89.9 | -51.7 | -31.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -37 | -76.8 | -89.9 | -51.7 | -31.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.94 | -2.63 | -3.03 | -1.53 | -0.739 |